Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.

ABSTRACT:

Background

Targeted sequencing of circulating tumour DNA (ctDNA) is a promising tool to monitor dynamic changes in the variant allele frequencies (VAF) of genomic alterations and predict clinical outcomes in patients with advanced urothelial carcinoma (UC).

Methods

We performed targeted sequencing of 182 serial ctDNA samples from 53 patients with advanced UC.

Results

Serial ctDNA-derived metrics predicted the clinical outcomes in patients with advanced UC. Combining serial ctDNA aggregate VAF (aVAF) values with clinical factors, including age, sex, and liver metastasis, improved the performance of prognostic models. An increase of the ctDNA aVAF by ≥1 in serial ctDNA samples predicted disease progression within 6 months in 90% of patients. The majority of patients wit

SUBMITTER: Shohdy KS 

PROVIDER: S-EPMC8810988 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature